Keyphrases
First-in-human Study
100%
Advanced Cancer
100%
Advanced or Metastatic
100%
Metastatic Cancer
100%
Notch Inhibitor
100%
Notch Signaling
44%
Recommended Phase 2 Dose
33%
Antitumor Activity
22%
Patients with Advanced Cancer
22%
Inhibition Rate
22%
Clinical Activity
22%
Monotherapy
22%
Tolerability
22%
Thrice Weekly
22%
Targeted Agents
11%
Dose-limiting Toxicity
11%
Pharmacodynamic Interactions
11%
Adverse Events
11%
Tumor Necrosis
11%
Heavily Pretreated Patients
11%
Colitis
11%
Thrombocytopenia
11%
Dose Escalation
11%
Ankyrin Repeat
11%
Patients with Breast Cancer
11%
Regulated Genes
11%
Metabolic Response
11%
Human Malignancies
11%
Safety Assessment
11%
Nausea
11%
Adenoid Cystic Carcinoma
11%
Biologic Effect
11%
Pharmacokinetic Profile
11%
Pharmacodynamics
11%
γ-secretase Inhibitor
11%
Cyclin D1 (CCND1)
11%
Oral Dose
11%
Tumor Shrinkage
11%
Gastrointestinal
11%
Transmembrane Domain
11%
Pharmacokinetic Parameters
11%
Leiomyosarcoma
11%
Overexpression
11%
Hairy and Enhancer of Split 1
11%
Pharmacology, Toxicology and Pharmaceutical Science
Advanced Cancer
100%
Human Study
100%
Metastasis
100%
Tolerability
22%
Antitumor Activity
22%
Monotherapy
22%
Pharmacodynamics
22%
Ankyrin
11%
Tumor Necrosis
11%
Thrombocytopenia
11%
Notch Receptor
11%
Adenoid Cystic Carcinoma
11%
Nausea
11%
Cyclin D1
11%
Receptor
11%
Adverse Event
11%
Neoplasm
11%
Pharmacokinetic
11%
Pharmacokinetic Parameter
11%
Breast Cancer
11%
Chemotherapy
11%
Colitis
11%
Secretase
11%
Leiomyosarcoma
11%